Intensity Therapeutics, Inc. INTS

INTS Company Overview

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of proprietary intratumoral cancer therapies designed to disperse throughout tumors and diffuse into cancer cells. The company operates within the oncology and biopharmaceutical industries, with a primary emphasis on solid tumor treatment and immune-based cancer therapeutics. Its lead product candidate, INT230-6, is being evaluated in clinical trials for multiple advanced and metastatic cancers. The company’s approach is intended to directly kill tumor cells locally while potentially stimulating systemic adaptive immune responses.

The company’s principal revenue activity has historically consisted of research and development programs rather than commercial product sales, as it remains in the clinical development stage. Intensity Therapeutics has positioned itself around a differentiated localized delivery platform aimed at overcoming limitations associated with conventional systemic chemotherapy and immunotherapy approaches. The company was founded in 2012 and has evolved from an early-stage oncology research enterprise into a publicly traded biotechnology company listed on the Nasdaq under the ticker INTS following its public market debut in 2023.